Iteos Therapeutics Ownership
| ITOS Stock | USD 7.40 0.13 1.79% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Iteos |
Iteos Stock Ownership Analysis
About 95.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.43. Some equities with similar Price to Book (P/B) outperform the market in the long run. Iteos Therapeutics recorded a loss per share of 3.14. The entity had not issued any dividends in recent years. Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Iteos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people. To learn more about Iteos Therapeutics call Michel Detheux at 339 217 0161 or check out https://www.iteostherapeutics.com.Besides selling stocks to institutional investors, Iteos Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Iteos Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Iteos Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Iteos Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Iteos Therapeutics Insider Trades History
Only 1.25% of Iteos Therapeutics are currently held by insiders. Unlike Iteos Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Iteos Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Iteos Therapeutics' insider trades
Iteos Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Iteos Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Iteos Therapeutics backward and forwards among themselves. Iteos Therapeutics' institutional investor refers to the entity that pools money to purchase Iteos Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.2 M | State Street Corp | 2024-09-30 | 1.2 M | Vestal Point Capital Lp | 2024-09-30 | 1 M | Jpmorgan Chase & Co | 2024-09-30 | 934.6 K | Goldman Sachs Group Inc | 2024-09-30 | 913 K | Geode Capital Management, Llc | 2024-09-30 | 640.4 K | Renaissance Technologies Corp | 2024-09-30 | 536.4 K | K2 Principal Fund Lp | 2024-09-30 | 535 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 501.4 K | Blackrock Inc | 2024-09-30 | 3.9 M | Ra Capital Management, Llc | 2024-09-30 | 3.2 M |
Iteos Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iteos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iteos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Iteos Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Iteos Therapeutics Outstanding Bonds
Iteos Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Iteos Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Iteos bonds can be classified according to their maturity, which is the date when Iteos Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ITC HLDGS P Corp BondUS465685AH81 | View | |
| ITC HLDGS P Corp BondUS465685AK11 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US465685AQ80 Corp BondUS465685AQ80 | View | |
| ITC HLDGS P Corp BondUS465685AP08 | View | |
| ITC 495 22 SEP 27 Corp BondUS465685AR63 | View |
Iteos Therapeutics Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 21st of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.